Castle Biosciences Q3 2025 Revenue Report
Castle Biosciences, Inc. (NASDAQ: CSTL), a leader in innovative diagnostic solutions, recently announced its financial results for the third quarter of 2025, showcasing a remarkable revenue of $83 million. This revenue signifies a robust growth trajectory, particularly in the non-dermatologic sector where there was a 67% increase compared to Q3 2024.
Key Highlights from Q3 2025
Several notable achievements marked this quarter. The Company successfully raised its full-year revenue guidance for 2025 from a range of $310-320 million to between $327-335 million, reflecting confidence in its growth strategy and market demand.
Test Report Volume Growth
In Q3 2025, Castle Biosciences delivered a total of 26,841 test reports, representing a 3% increase from the 26,010 reports in the same quarter of the previous year. Key tests driving this growth included DecisionDx-Melanoma and TissueCypher, both of which surpassed 10,000 test reports for the first time in a single quarter. This illustrates the increasing adoption and reliance on these advanced diagnostic tools.
Financial Performance Overview
The Company’s gross margin stood at 75%, slightly down from 79% in Q3 2024. Adjusted Gross Margin was reported at 77%. Furthermore, net cash provided by operations was $22.6 million, primarily driven by the strong performance in test volume and revenues.
Adjusted EBITDA and Net Loss
Adjusted EBITDA for Q3 2025 was recorded at $9.2 million, a significant drop from $21.6 million during the same period in 2024. The net loss for this quarter was $0.5 million, in sharp contrast to the net income of $2.3 million reported last year. Notably, a non-cash stock-based compensation expense of $12.1 million impacted the net earnings this quarter.
Continuous Innovation and New Offerings
Castle Biosciences announced the launch of AdvanceAD-Tx™, a groundbreaking test intended to aid in the treatment decision-making for patients aged 12 and older with moderate-to-severe atopic dermatitis. This test is poised to fill a significant gap in the healthcare framework for dermatological conditions.
Recent Developments in Dermatology and Gastroenterology
During recent clinical conferences, new data on DecisionDx-Melanoma highlighted its capability to stratify risk for various melanoma subtypes. This advancement supports more tailored treatment planning, a vital aspect for enhancing patient outcomes. Furthermore, TissueCypher's risk stratification data revealed potential for identifying Barrett’s Esophagus patients at risk of progression towards esophageal cancer, emphasizing Castle’s commitment to innovative solutions in patient care.
Looking Ahead
As the company progresses towards the end of 2025, it remains focused on its core testing franchises while expanding its product offerings. The positive market reception of AdvanceAD-Tx demonstrates the company's ability to innovate continuously, ensuring it meets the evolving demands of healthcare professionals and patients alike. The leadership team at Castle Biosciences expresses optimism about the future, as they work toward achieving their new revenue guidance and maintaining an upward trajectory in test report growth.
Frequently Asked Questions
What were Castle Biosciences' revenues in Q3 2025?
Castle Biosciences reported revenues of $83 million in Q3 2025.
What was the reason for adjusting the revenue guidance for 2025?
The revenue guidance was adjusted upward due to strong performance in both dermatologic and gastrointestinal testing franchises.
How many total test reports were delivered in Q3 2025?
A total of 26,841 test reports were delivered during Q3 2025.
What is AdvanceAD-Tx™?
AdvanceAD-Tx™ is a new genetic test designed to guide systemic treatment decision-making in patients with atopic dermatitis.
How has Castle Biosciences performed compared to last year?
Compared to Q3 2024, Castle Biosciences has shown growth in revenue and test report volume, though earnings decreased due to increased operational costs and stock-based compensation.
